DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “outperform” rating restated by analysts at BMO Capital Markets in a report issued on Tuesday. They currently have a $90.00 target price on the medical device company’s stock, down from their prior target price of $105.00. BMO Capital Markets’ target price points to a potential upside of 26.21% from the company’s current price.

Several other research analysts have also commented on the stock. Cowen and Company reiterated an “outperform” rating and set a $90.00 price objective on shares of DexCom in a research note on Tuesday, April 18th. BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Jefferies Group LLC reduced their price objective on shares of DexCom to $91.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. Finally, William Blair reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $87.00.

DexCom (NASDAQ:DXCM) remained flat at $71.31 during midday trading on Tuesday. 1,057,393 shares of the company traded hands. The stock has a 50 day moving average of $72.14 and a 200 day moving average of $75.59. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38. The company’s market cap is $6.17 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. DexCom’s revenue was up 24.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.24) EPS. Analysts anticipate that DexCom will post ($0.77) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/08/dexcom-inc-dxcm-given-outperform-rating-at-bmo-capital-markets.html.

In other news, EVP Andrew K. Balo sold 3,200 shares of the company’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $71.93, for a total value of $230,176.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 8,649 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total transaction of $591,505.11. Following the completion of the sale, the chief executive officer now directly owns 347,329 shares in the company, valued at $23,753,830.31. The disclosure for this sale can be found here. Insiders sold a total of 36,331 shares of company stock worth $2,548,619 over the last ninety days. Insiders own 1.70% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in DXCM. Independent Portfolio Consultants Inc. raised its stake in shares of DexCom by 97.6% in the first quarter. Independent Portfolio Consultants Inc. now owns 2,490 shares of the medical device company’s stock worth $211,000 after buying an additional 1,230 shares during the last quarter. C WorldWide Group Holding A S raised its stake in shares of DexCom by 10.4% in the first quarter. C WorldWide Group Holding A S now owns 51,244 shares of the medical device company’s stock worth $4,342,000 after buying an additional 4,819 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in shares of DexCom by 12.5% in the first quarter. Essex Investment Management Co. LLC now owns 16,693 shares of the medical device company’s stock worth $1,414,000 after buying an additional 1,853 shares during the last quarter. Weatherly Asset Management L. P. raised its stake in shares of DexCom by 94.1% in the first quarter. Weatherly Asset Management L. P. now owns 8,123 shares of the medical device company’s stock worth $688,000 after buying an additional 3,938 shares during the last quarter. Finally, Sit Investment Associates Inc. raised its stake in shares of DexCom by 159.8% in the first quarter. Sit Investment Associates Inc. now owns 23,900 shares of the medical device company’s stock worth $2,025,000 after buying an additional 14,700 shares during the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.